Update on the Use of Nanocarriers and Drug Delivery Systems and Future Directions in Cervical Cancer

J Immunol Res. 2022 May 4:2022:1636908. doi: 10.1155/2022/1636908. eCollection 2022.

Abstract

Cervical cancer represents a major health problem among females due to its increased mortality rate. The conventional therapies are very aggressive and unsatisfactory when it comes to survival rate, especially in terminal stages, which requires the development of new treatment alternatives. With the use of nanotechnology, various chemotherapeutic drugs can be transported via nanocarriers directly to cervical cancerous cells, thus skipping the hepatic first-pass effect and decreasing the rate of chemotherapy side effects. This review comprises various drug delivery systems that were applied in cervical cancer, such as lipid-based nanocarriers, polymeric and dendrimeric nanoparticles, carbon-based nanoparticles, metallic nanoparticles, inorganic nanoparticles, micellar nanocarriers, and protein and polysaccharide nanoparticles. Nanoparticles have a great therapeutic potential by increasing the pharmacological activity, drug solubility, and bioavailability. Through their mechanisms, they highly increase the toxicity in the targeted cervical tumor cells or tissues by linking to specific ligands. In addition, a nondifferentiable model is proposed through holographic implementation in the dynamics of drug delivery dynamics. As any hologram functions as a deep learning process, the artificial intelligence can be proposed as a new analyzing method in cervical cancer.

Publication types

  • Review

MeSH terms

  • Antineoplastic Agents* / adverse effects
  • Artificial Intelligence
  • Drug Carriers
  • Drug Delivery Systems / methods
  • Female
  • Humans
  • Nanoparticles*
  • Uterine Cervical Neoplasms* / drug therapy

Substances

  • Antineoplastic Agents
  • Drug Carriers